Today: 9 June 2026
Netflix stock ends higher as Trump steps back from Warner Bros battle, then slips after hours
5 February 2026
1 min read

Netflix stock ends higher as Trump steps back from Warner Bros battle, then slips after hours

New York, Feb 5, 2026, 17:27 EST — After-hours

  • Netflix ended the day up 0.9%, then slipped roughly 0.4% in after-hours trading
  • Trump said he won’t step into Netflix’s dispute with Paramount Skydance over Warner Bros Discovery
  • Investors have their eyes on the U.S. antitrust review and the February 20 deadline linked to Paramount’s offer

Netflix (NFLX.O) shares ticked up 0.9% to finish at $80.87 on Thursday, then slipped roughly 0.4% to $80.52 in after-hours trading, which extends beyond the 4 p.m. close. The stock reaction came after U.S. President Donald Trump said he would not get involved in Netflix’s dispute with Paramount Skydance over Warner Bros Discovery.

The comment matters because the Warner Bros process has become as much a regulatory saga as a deal. Trump stepping aside cuts one political factor out, but it doesn’t alter the main obstacle: the U.S. Justice Department’s review, which could drag on for months and end with conditions, delays, or even a block.

Traders have zeroed in on headlines about the proposed acquisition, causing the stock to jump with every fresh update. As a result, Netflix finds itself in an unusual position: company performance takes a backseat while Washington scrutinizes the deal’s structure and timing.

On Tuesday, U.S. senators grilled Netflix co-CEO Ted Sarandos during a hearing focused on whether the deal would stifle competition and limit choices for consumers and workers. Senator Mike Lee dubbed Netflix “the one platform to rule them all,” while Sarandos described the fight for viewers’ attention as a “zero-sum game.” Reuters

Netflix closed higher despite a sharp sell-off on Wall Street, where the Nasdaq dropped 1.59% and the S&P 500 fell 1.23%. Investors fretted over hefty AI spending projections and softer U.S. labor data.

The stock showed volatile moves throughout the week. It dropped 3.4% on Tuesday but bounced back over the following two days, closing Thursday at $80.87.

According to an SEC filing, director Reed Hastings sold shares on Feb. 2 by exercising options under a Rule 10b5-1 plan, a pre-set trading arrangement for insiders. The sale happened in three batches, with weighted average prices of $83.2223, $84.0947, and $84.9551, the document revealed.

Netflix has put forward an $82.7 billion bid to acquire Warner Bros Discovery’s streaming and studio businesses. At the same time, Paramount Skydance is pushing a rival hostile offer. Warner Bros shareholders are set to vote on the Netflix deal in March. Paramount has also extended its tender-offer deadline to Feb. 20, according to an earlier Reuters report.

The risk points one way if the process sours. Regulators might push for concessions that undercut the deal’s value or drag out the timeline, leaving shares in limbo. On top of that, fresh political noise could shift the odds once more.

Investors are set to focus on any new cues from antitrust regulators, updates on the Warner Bros process filings, and possible shifts in bidder terms ahead of the Feb. 20 deadline, all leading into Friday’s session.

Stock Market Today

  • Regentis Biomaterials Plans European Surgeon Training for GelrinC Implant
    June 9, 2026, 9:53 AM EDT. Regentis Biomaterials' shares edged down to $1.28 ahead of the New York open as the company outlined its European launch strategy for GelrinC, a knee cartilage repair hydrogel implant. The Israeli regenerative-medicine firm will begin surgeon training in Q3 at Humanitas Research Hospital in Milan, marking a key step between CE Mark regulatory clearance and commercial use in Europe. GelrinC's "off-the-shelf" design contrasts with custom-grown products, aiming to ease adoption. However, key uncertainties remain around FDA approval in the U.S., clinical trial outcomes, market acceptance, reimbursement, and competition from established implants by Smith+Nephew and Vericel. Regentis raised $10 million at its December 2025 IPO to fund pivotal U.S. trials and PMA submission. CEO Dr. Ehud Geller called training "critical" for physician adoption ahead of broader rollout.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Dow Jones today: Index slides about 1% as Alphabet capex plan stirs fresh AI jitters
Previous Story

Dow Jones today: Index slides about 1% as Alphabet capex plan stirs fresh AI jitters

Robinhood stock tumbles nearly 10% as bitcoin breaks lower with earnings days away
Next Story

Robinhood stock tumbles nearly 10% as bitcoin breaks lower with earnings days away

Go toTop